arrow
P

Peter Dreger

universitaetsklinkum heidelberg
H指数:82
被引数:2.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world CAR-T practice patterns in patients with mantle cell lymphoma: an international survey on behalf of the EBMT lymphoma working party

套细胞淋巴瘤患者中真实世界CAR-T实践模式:EBMT淋巴瘤工作组发起的一项国际调查

2026-08-180
PRE
A distinct CAR-T cell phenotype mediates therapeutic response at limited doses

一种独特的CAR-T细胞表型介导了有限剂量下的治疗效果

2026-07-290
OA
Fludarabine combined with treosulfan or total body irradiation as a conditioning therapy before allogeneic hematopoietic stem cell transplantation in acute lymphoblastic leukemia. A retrospective matched-pair analysis from the ALWP of the EBMT

氟达拉滨联合曲奥舒凡或全身照射作为异基因造血干细胞移植前急性淋巴细胞白血病的预处理疗法。来自EBMT ALWP的回顾性配对分析

2026-07-080
OA
Feasibility and safety of rapid glofitamab ramp-up

快速提升glofitamab的可行性与安全性

Leukemia
IF13.4
2026-07-010
OAAI
Non-myeloablative versus reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients aged ≥65: a study from the ALWP of EBMT

非清髓性预处理与减低强度预处理在≥65岁急性髓系白血病患者异基因造血干细胞移植中的比较:EBMT ALWP的研究

2026-06-210
PRE
The impact of IPI risk factors on CAR T-cell therapy or allogeneic stem cell transplantation for treatment of relapsed or refractory large B-cell lymphoma (LBCL)

IPI风险因素对复发或难治性大B细胞淋巴瘤(LBCL)治疗中CAR T细胞疗法或同种异体干细胞移植的影响

2026-06-190
PRE
Allogeneic hematopoietic cell transplantation for T-cell/histiocyte-rich large B-cell lymphoma: An EBMT lymphoma working party study

异基因造血细胞移植治疗T细胞/组织细胞富集型大B细胞淋巴瘤:一项EBMT淋巴瘤工作组研究

Leukemia
IF13.4
2026-06-150
OAAI
Impact of fludarabine dosage on outcomes in large B-cell lymphoma patients treated with CAR T-cell therapy: a retrospective study of the CTIWP of the EBMT

氟达拉滨剂量对接受CAR T细胞治疗的大B细胞淋巴瘤患者预后的影响:EBMT CTIWP的一项回顾性研究

2026-06-060
PRE
Survival trends in young adults with acute leukaemia after AHSCT in Germany: comparisons with younger and older patients

德国年轻成人急性白血病自体造血干细胞移植后的生存趋势:与更年轻和更年长患者的比较

2026-04-120
PREAI
Haploidentical transplantation with post-transplant cyclophosphamide is not inferior to 9/10-MUD transplantation with ATG in patients with myeloid malignancies

单倍型相合移植联合移植后环磷酰胺不劣于9/10相合无关供者移植联合抗胸腺细胞球蛋白在髓系恶性肿瘤患者中的应用

2026-04-080
OAAI
Results of brexucabtagene-autoleucel for patients with relapsed/refractory Mantle Cell Lymphoma in the routine setting in Germany and Switzerland

德国和瑞士常规环境中,Brexucabtagene-autoleucel治疗复发/难治性套细胞淋巴瘤患者的疗效结果

2026-01-160
OAAI
Autologous stem cell transplantation in NK/T-cell lymphoma: Prognostic impact of EBV-DNA in a multinational cohort—A study by the EBMT Lymphoma Working Party

自体干细胞移植在NK/T细胞淋巴瘤中的应用:EBV-DNA在跨国队列中的预后影响——EBMT淋巴瘤工作组的研究

2025-08-150
OAAI
Allogeneic hematopoietic cell transplantation for older patients with Philadelphia-positive acute lymphoblastic leukemia. A study by the Acute Leukemia Working Party of the EBMT

异基因造血细胞移植治疗费城染色体阳性急性淋巴细胞白血病的老年患者。EBMT急性白血病工作组的研究。

2025-07-160
PRE
Bridging intensity is associated with impaired hematopoietic recovery after BCMA CAR-T therapy for multiple myeloma

桥接强度与多发性骨髓瘤患者接受BCMA CAR-T疗法后的造血恢复受损相关

2025-04-250
OAAI